March 2026
PTSD
What March 2026's 13 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research on PTSD in March 2026 focused heavily on psychedelic and pharmacological treatments, with meta-analyses showing MDMA-assisted therapy reduces PTSD symptoms (SMDs around -0.71 to -1.19) but with very low certainty evidence and concerns about blinding and expectancy. Ketamine and ibogaine also showed promise, with ketamine's dissociative effects resembling PTSD brain states and ibogaine linked to brain network changes correlating with symptom improvement. However, evidence is limited by small samples, short follow-ups, and methodological flaws, and no definitive conclusions can be drawn for most treatments.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 13 matching studies were reviewed; the 12 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mindfulness-Based Intervention to Lower Post-Traumatic Stress Disorder in Survivors of Domestic Violence 2026 | quasi-experimental one-group pre-test post-test design | 7 | Supports | A mindfulness-based intervention significantly lowered PTSD levels in domestic violence survivors, with reductions in intrusion, avoidance, and hypervigilance scores. |
| A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD 2026 | systematic review and meta-analysis | 286 | Supports | MDMA-assisted therapy reduced PTSD symptoms more than control conditions (Hedges' g = -0.71), with higher dosing sessions and cumulative dose associated with larger effects, though certainty was low. |
| Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review 2026 | review | Supports | The review argues that (R,S)-ketamine's therapeutic effects involve specific brain circuits and BDNF-TrkB signaling, while NMDA receptor antagonism may be unrelated to efficacy. | |
| Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder 2026 | observational study | 30 | Supports | Ibogaine-induced posterior shifts in high-beta brain networks correlated with PTSD symptom improvements and may serve as a biomarker for its therapeutic effects. |
| State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder 2026 | review | Mixed | MDMA-assisted psychotherapy for PTSD has shown promising outcomes in randomized controlled trials but faces significant methodological limitations and has not received FDA approval due to insufficient evidence. | |
| Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder 2026 | review | Supports | Prazosin has the best evidence base for treating PTSD-related nightmares, and alternative alpha-1 blockers may be effective when prazosin is not feasible. | |
| Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes 2026 | systematic review and meta-analysis | 298 | Supports | MDMA-assisted therapy was associated with reductions in PTSD symptom severity and dissociative symptoms, and may improve functioning, but the certainty of the evidence was very low. |
| Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review 2026 | review | Supports | MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD, though caution is needed due to expectancy and blinding limitations. | |
| Flashbacks Through Time: Historical Development and Current Use of the Term "Flashback" in Psychedelic and Post-Traumatic Stress Disorder Research. 2026 | historical analysis | Unclear | Argues that the term 'flashback' has been applied inconsistently across psychedelic and PTSD research, leading to conceptual confusion that hinders scientific clarity. | |
| Toward dimensional body consciousness impairments in post-traumatic stress disorder and its dissociative subtype: A predictive processing approach. 2026 | theoretical or philosophical paper | Unclear | Proposes that dissociative and non-dissociative PTSD involve distinct disruptions in the predictive processing hierarchy of prior beliefs, interoception, and exteroception, with sense of agency impairments specific to the dissociative subtype. | |
| Brain State Dynamics in Ketamine-Induced Dissociation Resemble Those in Posttraumatic Stress Disorder. 2026 | observational cohort with experimental manipulation and secondary analysis of clinical trial data | 108 | Supports | Dissociative states, whether induced by ketamine in healthy volunteers or present in PTSD patients, are associated with increased dominance of the default mode network meta-state and decreased dominance of the somatomotor network meta-state. |
| Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms. 2026 | theoretical or philosophical paper | Unclear | Proposes that combining ketamine and prazosin may improve PTSD and AUD outcomes through complementary mechanisms, though untested in trials. |
A mindfulness-based intervention significantly lowered PTSD levels in domestic violence survivors, with reductions in intrusion, avoidance, and hypervigilance scores.
quasi-experimental one-group pre-test post-test design Sample size: 7
MDMA-assisted therapy reduced PTSD symptoms more than control conditions (Hedges' g = -0.71), with higher dosing sessions and cumulative dose associated with larger effects, though certainty was low.
systematic review and meta-analysis Sample size: 286
The review argues that (R,S)-ketamine's therapeutic effects involve specific brain circuits and BDNF-TrkB signaling, while NMDA receptor antagonism may be unrelated to efficacy.
review
Ibogaine-induced posterior shifts in high-beta brain networks correlated with PTSD symptom improvements and may serve as a biomarker for its therapeutic effects.
observational study Sample size: 30
MDMA-assisted psychotherapy for PTSD has shown promising outcomes in randomized controlled trials but faces significant methodological limitations and has not received FDA approval due to insufficient evidence.
review
Prazosin has the best evidence base for treating PTSD-related nightmares, and alternative alpha-1 blockers may be effective when prazosin is not feasible.
review
MDMA-assisted therapy was associated with reductions in PTSD symptom severity and dissociative symptoms, and may improve functioning, but the certainty of the evidence was very low.
systematic review and meta-analysis Sample size: 298
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD, though caution is needed due to expectancy and blinding limitations.
review
Argues that the term 'flashback' has been applied inconsistently across psychedelic and PTSD research, leading to conceptual confusion that hinders scientific clarity.
historical analysis
Proposes that dissociative and non-dissociative PTSD involve distinct disruptions in the predictive processing hierarchy of prior beliefs, interoception, and exteroception, with sense of agency impairments specific to the dissociative subtype.
theoretical or philosophical paper
Dissociative states, whether induced by ketamine in healthy volunteers or present in PTSD patients, are associated with increased dominance of the default mode network meta-state and decreased dominance of the somatomotor network meta-state.
observational cohort with experimental manipulation and secondary analysis of clinical trial data Sample size: 108
Proposes that combining ketamine and prazosin may improve PTSD and AUD outcomes through complementary mechanisms, though untested in trials.
theoretical or philosophical paper
Points of agreement
- MDMA-assisted therapy shows consistent evidence of reducing PTSD symptoms across meta-analyses, though with low certainty.
- Ketamine and ibogaine show promise for PTSD, with ketamine's dissociative effects resembling PTSD brain states and ibogaine linked to brain network changes.
- Prazosin is supported for PTSD-related nightmares, with alternative alpha-1 blockers as potential options.
- Methodological limitations such as blinding, expectancy, and small samples are common across psychedelic and pharmacological studies.
Conflicts
- One meta-analysis (article 27849) reported a smaller effect size (g = -0.71) compared to another (article 25094) with SMD = -1.19, possibly due to different inclusion criteria or analyses.
- The review on MDMA-AT (article 25110) notes FDA declined approval due to insufficient evidence, while other reviews (article 24928) suggest MDMA has the greatest support, reflecting differing interpretations of the evidence base.
Gaps
- Durability of treatment effects beyond short-term follow-up is not well established.
- Blinding and expectancy effects are inadequately addressed in most psychedelic trials.
- Sample sizes are small, limiting generalizability.
- Head-to-head comparisons of different treatment models and active comparator conditions are lacking.
- Safety monitoring and long-term adverse effects are insufficiently studied.
- Most research focuses on MDMA and ketamine; other psychedelics like psilocybin and LSD require more RCTs.